Treatment of chronic hepatitis C with amantadine

Digestive Diseases and Sciences

Volumn 42, Issue 8, 1997, Pages 1681-1687

  Smith, Jill Palmer ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Amantadine; Hepatitis C; Interferon; Liver; Viral hepatitis

Indexed keywords

AMANTADINE; INTERFERON;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEPATITIS C; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RNA ANALYSIS; STATISTICAL ANALYSIS;

ADOLESCENT; AGED; ALANINE TRANSAMINASE; AMANTADINE; ANTIVIRAL AGENTS; CHRONIC DISEASE; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RNA, VIRAL;

EID: 0030822539     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018857314351     Document Type: Article

References (37)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362, 1989
2. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL: An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244:362-364, 1989
3. Stevens CE, Taylor PE, Pindyck J, Choo QL, Bradley DW, Kuo G, Houghton M: Epidemiology of hepatitis C virus: A preliminary study in volunteer blood donors. JAMA 263:49-53, 1990
4. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, VanThiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter randomized, controlled trial. N Engl J Med 321:1501-1506, 1989
5. Lunel F, Musset L, Cacoub P, Frangeul L, Cresta P, Perrin M, Grippon P, Hoang C, Piette JC, Huraux JM, Opolon P: Cryoglobulinemia in chronic liver diseases: Role of hepatitis C virus and liver damage. Gastroenterology 106:1291-1300, 1994
6. Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, Zilio P, Vernocchi A, Massazza M, Vendramin G, Tanzi E, Zanetti A: Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 330:751-756, 1994
7. DeCastro M, Sanchez J, Herrera JF, Chaves A, Duran R, Garcia-Buey L, Garcia-Monzon C, Sequi J, Moreno-Otero R: Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology 17:551-557, 1993
8. Wilson SE, Lee WM, Murakami C, Weng J, Moninger GA: Mooren's corneal ulcers and hepatitis C virus infection. N Engl J Med 329:62, 1993 (letter)
9. Pawlotsky JM, Ben Yahia M, Andre C, Voisin MC, Intrator L, Roudot-Thoraval F, Deforges L, Duvoux C, Zafrani ES, Duval J, Dhumeaux D: Immunologic disorders in C virus chronic active hepatitis: A prospective case-control study. Hepatology 19:841-848, 1994
10. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE, Meeks EL, Beach MJ, Sentinenl Counties Chronic Non-A, Non-B Hepatitis Study Team: The natural history of community-acquired hepatitis C in the United States. N Engl J Med 327:1899-1905, 1992
11. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger B, Gitnick G, Knodell RG, Perrillo RP, Stevens CE, Hollingsworth CG, National Heart, Lung and Blood Institute Study Group: Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 327:1906-1911, 1992
12. Tong MJ, el-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332:1463-1466, 1995
13. Liang TJ, Jeffers LJ, Reddy KR, De Medina M, Parker IT, Cheinquer H, Idrovo V, Rahassa A, Schiff ER: Viral pathogenesis of hepatocellular carcinoma in the United States. Hepatology 18:1326-1333, 1993
14. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yahuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, Kawashima T: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797-1801, 1993
15. Ascher NL, Lake JR, Emond J, Roberts J: Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 20(suppl):24-27, 1994
16. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortega TJ, Gibas A, Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med 321:1501-1506, 1989
17. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH: Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506-1510, 1989
18. Tine F, Magrin S, Craxi A, Pagliaro L: Interferon for non-A, non-B chronic hepatitis: A meta-analysis of randomized clinical trials. J Hepatol 13:192-199, 1991
19. Taliani G, Furlan C, Grimaldi F, Clementi C, Lecce R, Manganaro M, Duca F, DeBac C: One course versus two courses of recombinant alpha interferon in chronic hepatitis C. Arch Virol Suppl 4:294-298, 1992
20. Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N, Lemonnier C, Degott C, Erlinger S, Benhamou JP: Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 109:156-165, 1995
21. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, Payen JL, Sajus M, Costa JM, Vidaud M, Chaput JC, Multicenter Study Group: A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 332:1457-1462, 1995
22. Diodati G, Bonetti P, Noventa F, Casarin C, Rugge M, Scaccabarozzi S, Tagger A, Pollice L, Tremolada F, Davite C, Realdi G, Ruol A: Treatment of chronic hepatitis C with recombinant human interferon alpha-2a: Results of a randomized controlled clinical trial. Hepatology 19:1-5, 1994
23. Kakumu S, Yoshika K, Tanaka K, Higashi Y, Kurokawa S, Hirofugi U, Kusakahe A: Long-term carriage of hepatitis C with normal aminotransferase after interferon treatment in patients with chronic hepatitis C. J Med Virol 41:65-70, 1993
24. Kleter GE, Brouwer JT, Heijtink RA, Schalm SW, Quint WG: Detection of hepatitis C virus RNA in patients with chronic hepatitis C infections during and after alpha interferon. Antimicrob Agents Chemother 37:595-597, 1993
25. Urdea MS, Horn T, Fultz TJ, Anderson M, Running JA, Hamren S, Ahle D, Chang CA: Branched DNA amplication multimers for the sensitive, direct detection of human hepatitis viruses. Nucleic Acids Symp Ser 24:197-200, 1991
26. Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokam M, Neuwald PD, Wilber JC: Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341:1501-1509, 1993
27. Stokes P, Lopez WC, Balart LA: Effects of short-term corticosleroid therapy in patients with chronic non-A, non-B hepatitis. Gastroenterology 92:1783, 1993 (abstract)
28. Di Bisceglie AM, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, Axiotis CA, Waggoner JG, Park Y, Hoofnagle JH: A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16:649-654, 1992
29. Monto AS, Gunn RA, Bandyk MG, King CL: Prevention of Russian influenza by amantadine. JAMA 241:1003-1007, 1979
30. Vale JA, Maclean KS: Amantadine induced congestive heart failure. Lancet 1:548, 1977 (letter)
31. Bleidner WE, Harmon JB, Hewes WE, Lynes TE, Hermann EC: Absorption, distribution and excretion of amantadine hydrochloride. J Pharmacol Exp Ther 150:484-490, 1965
32. Ing TS, Daugirdas JT, Soung LS, Klawans HL, Mahurkar SD, Hayashi JA, Geis WP, Hano JE: Toxic effects of amantadine in patients with renal failure. Can Med Assoc J 120:695-698, 1979
33. Wright PF, Khan KT, Oxman MN, Schwachman H: Evaluation of the safety of amantadine HCl and the role of respiratory viral infection in children with cystic fibrosis. J Inf Dis 134:144-149, 1976
34. Aoki FY, Sitar DS: Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacol 14:35-51, 1988
35. Oxford JS, Galbraith A: Antiviral activity of amantadine: a review of laboratory and clinical data. Pharmacol Ther 11:181-262, 1980
36. Skehel JJ, Hay AJ, Armstrong JA: On the mechanism of inhibition of influenza virus replication by amantadine hydrochloride. J Gen Virol 38:97-110, 1978
37. 3H-amantadine HCl. Chem Pharm Bull 17:841-843, 1969